Nordic EMBL Partnership
The purpose of the Nordic EMBL Partnership for Molecular Medicine is to facilitate scientific collaboration and thereby capitalize on both intellectual and material resources within the Nordic region in order to exploit emerging technologies and to develop molecular and translational medicine.
University rectors and Centre Directors from the four Nordic EMBL Partnership nodes, and the EMBL General Director Iain Mattaj. Photo: Lise Balsby, University of Aarhus.
The partnership was first established as a joint venture (2008-2012) between the EMBL (European Molecular Biology Laboratory) and the Universities of Helsinki (Finland), Umeå (Sweden) and Oslo (Norway), and involved the building of national sister institutions in the three countries. The impact and success of the Nordic EMBL Partnership was recognized in 2013 with the signing of a renewed partnership agreement for an extended period of 10 years (2013-2023).
The Nordic EMBL Partnership network expanded in 2013 when the Danish Research Institute of Translational Neuroscience (DANDRITE) at Aarhus University became the Danish node. The Partnership now consists of four research centres, with around 50 PIs and 500 employees.
The four Nordic nodes: a strong network, with complementary strengths
The signed agreement summarises each partner’s contribution to the Partnership.
By extending the EMBL’s recognised research strengths in areas such as cell biology and biophysics, developmental biology, genome biology and bioinformatics and structural biology; the individual nodes of theNordic EMBL Partnership for Molecular Medicine contribute the following complementary strengths:
DANDRITE: Molecular and translational neuroscience
FIMM: Human genomics, systems and precision medicine
MIMS: Microbial pathogenicity and molecular infection medicine
NCMM: Molecular mechanisms of disease
All four nodes are further supported by the EMBL, through access to scientific infrastructure, services and training, and through the EMBL’s complementary basic molecular research focus which helps to further enhance the translational aspects of the four nodes’ research. The majority of the group leaders at the nodes are young scientists recruited through international calls on the basis of scientific excellence and the EMBL model for recruitments.
Furthermore, each partner has adopted the EMBL model for international recruitment, staff turnover and scientific reviews. The coordination between the Nordic nodes and EMBL is overseen by a steering committee, constituted by two representatives from each node.
Committee of external experts
Scientific progress is reviewed regularly by a committee of external experts. In addition to their partnership with EMBL, the individual Nordic research centres engage in collaborations with other national partners, including research and public health institutes, hospitals and research councils, in order to establish an extensive Nordic network for molecular medicine. The partnership now also receives support from NordForsk as a Nordic Network of National Centers of Excellence.